Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER

* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential To Overcome Resistance Driven By Various EGFR C797S-Containing Mutations in Non-Small Cell Lung Cancer SHANGHAI, March 2, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech com...

2022-03-02 17:27 1624

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China

BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...

2022-03-02 10:37 2829

ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...

2022-03-02 09:07 1752

ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

Cambrex Expands Biopharmaceutical Services Business

EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...

2022-03-01 22:00 3829

Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...

2022-03-01 20:30 2527

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries

-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketin...

2022-03-01 17:30 3959

Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant

* The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 * SPL7013 showed potent antiviral activity and was virucidal against the Omicron varia...

2022-03-01 16:44 2959

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2022-03-01 08:48 4016

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, In...

2022-03-01 05:01 4125

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

BENGALURU, India, Feb. 28, 2022 /PRNewswire/ -- Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars bus...

2022-02-28 22:15 4318

Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

ALPS PHARMA LAUNCHES A NEW QUERCETIN DELIVERY COMPOSITION

HIDA, Japan, Feb. 28, 2022 /PRNewswire/ -- ALPS Pharmaceutical Ind. Co., Ltd. (President:Osamu Ushimaru), a global pharmaceutical company pioneering phytochemicals in medicine and food,today announced the launch of a water-soluble Quercetin delivery composition, Eubioflavonoid® derived from Sopho...

2022-02-28 09:19 1960

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis

HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (A...

2022-02-28 08:00 4089

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...

2022-02-27 18:30 6572

First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...

2022-02-25 22:04 3663

Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...

2022-02-25 22:00 3943

Jean-Luc Herbeaux to become Hovione CEO

LISBON, Portugal, Feb. 25, 2022 /PRNewswire/ -- Hovione today announced that the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective1st April 2022.

2022-02-25 22:00 3621

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation ("MTPC"), a Japanese pharma...

2022-02-25 10:00 2173

Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era

SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and ...

2022-02-24 20:00 2862

CSR Committee: PQE Group establishes internal department to enhance charitable and volunteering projects' governance

FLORENCE, Italy, Feb. 24, 2022 /PRNewswire/ -- For more than 4 years, PQE Group has been involved in spreading its culture of social responsibility all over the world, realizing amazing projects where employees are directly involved. For this reason, the company's ma...

2022-02-24 17:00 2412

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) has met its primary endpoint. The drug co-developed in Chi...

2022-02-24 13:34 2344

1 ... 294 295 296297298 299 300 ... 343